ArticleBMC urology2025
Microwave ablation versus combined microwave ablation and transarterial chemoembolization for T1a renal cell carcinoma: a Single-Center retrospective study.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate and compare the clinical efficacy and renal function outcomes of microwave ablation (MWA) alone versus MWA combined with transarterial chemoembolization (MWA + TACE) in patients with T1a renal cell carcinoma (RCC), with a focus on tumor complexity as defined by RENAL nephrometry scores. MATERIALS AND
methodsIn this retrospective single-center cohort study, 24 patients with T1a RCC were treated with either MWA (n = 14) or MWA + TACE (n = 10) between November 2020 and December 2024. Tumor response, residual enhancement rates, and renal function parameters were analyzed. RENAL scores were used to assess tumor complexity. Statistical comparisons between groups were performed using Student’s t-test and Fisher’s exact test.
resultsPatients treated with MWA + TACE had significantly higher RENAL scores than those treated with MWA (7.6 ± 1.6 vs. 6.1 ± 1.8; p = 0.03). Residual tumor enhancement was observed in 14.3% of patients in the MWA group, with no residual enhancement in the MWA + TACE group (p = 0.62). Post-procedural estimated glomerular filtration rate (eGFR) significantly declined in the MWA + TACE group (p = 0.04), while remaining stable in the MWA group (p = 0.39).
conclusionMWA alone appears to be a safe and effective treatment option for T1a RCC, providing comparable tumor control to MWA + TACE without additional risk of renal function deterioration. Although TACE was applied to more anatomically complex tumors with higher RENAL scores, its addition did not significantly improve oncological outcomes but was associated with a notable decline in renal function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.